Important Safety Information

• Renvela is contraindicated in patients with bowel obstruction. • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.  View additional Important Safety Information.

RenassistSM

Renassist is committed to helping patients access Sanofi Renal products.

Renassist is a team of dedicated case managers offering personalized service, education, and advocacy regarding reimbursement for Sanofi Renal products. Support is only a phone call away: 1-800-847-0069. The Renassist Helpline is available Monday-Friday, 8:30 AM - 5:00 PM EST.

Learn more about Renassist.

Insurance verification services

Renassist can contact your patients’ health insurers and prescription drug plans to determine available coverage for Sanofi Renal products. In addition, the Renassist team may be able to help facilitate prior authorizations and exceptions.

Learn more about Renassist insurance verification services.

Renal Patient Assistance Program (RPAP)*

The Renal Patient Assistance Program (RPAP) is designed for patients in financial need without coverage for Renvela® (sevelamer carbonate) under any prescription drug benefit, including commercial insurance, Medicare, Medicaid, or other government insurance programs.

Through partnership with the American Kidney Fund, Sanofi will provide qualifying patients with free medication. Learn more about the Renal Patient Assistance Program (RPAP).

Medicare Part D Assistance Program (PDAP)*

Sanofi's Renvela Medicare Part D Assistance Program (PDAP) provides a free supply of Renvela to eligible Medicare Part D patients who cannot afford their co-payments or coinsurance for the medication.

Learn more about the Medicare Part D Assistance Program (PDAP).

Forms and links

Visit the Forms and Links section at Renassist.com to get the assistance you need.

*Restrictions may apply to certain programs.

Information on Reimbursement

We're committed to helping your patients get coverage for Renvela through RenassistSM. Learn More

Contact Us

Sanofi US
500 Kendall Street
Cambridge, MA 02142

Tel: 617-252-7500
Fax: 617-252-7600
Toll free: 800-847-0069

Contact Sanofi

Indication

Renvela is indicated for the control of serum phosphorus in patients with CKD on dialysis.

Important Safety Information

  • Renvela is contraindicated in patients with bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • The most frequently occurring adverse reactions in a short-term study with sevelamer carbonate tablets were nausea and vomiting.
  • In a short-term study of sevelamer carbonate powder dosed three times daily, adverse events were similar to those reported for sevelamer carbonate tablets.
  • In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation.
  • Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using sevelamer suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renvela.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take Renvela with meals and to adhere to their prescribed diets.

Please see full Prescribing Information (PDF).